Truist raised the firm’s price target on Centessa (CNTA) to $38 from $33 and keeps a Buy rating on the shares. The firm is adjusting its model after re-examining the existing evidence across the orexin-2 receptor agonist class, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Expanding Beyond Sleep: Buy Rating on Centessa Pharmaceuticals Driven by Compelling Preclinical Data for Orexin Agonist CNT-9982
- Centessa price target raised to $33 from $30 at Truist
- Centessa price target raised to $38 from $35 at Needham
- 3 ‘Strong Buy’ Stocks to Buy Now, 1/1/2026, According to Top Analysts
- These Are the Most and Least Likely Biotech Takeover Targets for 2026